Previous close | N/A |
YTD return | N/A |
Expense ratio (net) | N/A |
Category | N/A |
Last cap gain | N/A |
Morningstar rating | N/A |
Morningstar risk rating | N/A |
Sustainability rating | N/A |
Net assets | N/A |
Beta (5Y monthly) | N/A |
Yield | N/A |
5y average return | N/A |
Holdings turnover | N/A |
Last dividend | N/A |
Average for category | N/A |
Inception date | N/A |
SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a partnership with Avance Clinical, a leading Contract Research Organization (CRO), to conduct a Phase II clinical trial in Australia. This trial aims to evaluate Oragenics' lead drug candidate, ONP-002, for mild Traumatic Brain Injury (TBI), commonly known as concussion. ONP-002, a novel chemical entity
SARASOTA, Fla., April 19, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April 18, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards. Specifically, the letter states that the Company is not in compliance with the conti
SARASOTA, Fla., April 01, 2024--Oragenics, Inc. (the "Company") (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has executed on its strategy to diversify its product development portfolio and makes progress in transforming the Company to create long term value. Some key items that have helped to improve t